Drugs / SPK-8016
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03734588 | Jan 2019 → Oct 2020 | hemophilia A | Spark Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPK-8016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03734588 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “adeno-associated viral vector” NCT03734588 ↗ |
| Route | Intravenous | “single intravenous (i.v.) administration of SPK-8016” NCT03734588 ↗ |